Effects of vitamin e, pentoxifylline and aprotinin on light-induced retinal injury.
OBJECTIVE
A considerable amount of clinical and experimental evidence exists suggesting the involvement of reactive oxygen species (ROS) in the etiology of light-induced retinal injury. The aim of this study was to investigate the protective role of vitamin E, pentoxifylline (PTX) and aprotinin against light-induced retinal injury in guinea pigs.


METHODS
Thirty adult male guinea pigs were divided into 5 groups of 6 animals each. The first group was used as control. The guinea pigs were kept in cyclic light for 2 weeks before the experiments. The animals were maintained in 12-hour light-dark cycles, before and after exposure to intense white fluorescent light, for as long as 12 h and then returned to cyclic light. Groups 3-5 received intraperitoneal injections of vitamin E, PTX and aprotinin, respectively. One eye of each animal was selected for histopathological evaluation and the other for biochemical assay. Retinal malondialdehyde (MDA) levels and the thickness of the outer nuclear layers were measured.


RESULTS
The compounds had the following relationships: vitamin E more than PTX more than aprotinin in preventing light-induced retinal damage. All 3 gave significant protection against the formation of MDA. Retinas of all 3 treatment groups had been protected from light-induced injury.


CONCLUSIONS
The intraperitoneal vitamin E, PTX and aprotinin supplementations may strengthen the antioxidant defense system because of decreased ROS, and these agents may play a role in treating light-induced retinal injury.
Yilmaz
Turgut
T
Department of Ophthalmology, Biochemistry, Firat University, School of Medicine, Elazig, Turkey. tyilmaz23@yahoo.com
Aydemir
Orhan
O
Ozercan
Ibrahim H
IH
Ustundağ
Bilal
B
D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use; D007611:Aprotinin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005126:Eye Burns / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D006168:Guinea Pigs; D007274:Injections, Intraperitoneal; D008027:Light / Q000009:adverse effects*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use*; D011833:Radiation Injuries, Experimental / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D011837:Radiation-Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D012160:Retina / Q000187:drug effects / Q000293:injuries* / Q000378:metabolism; D012164:Retinal Diseases / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013053:Spectrophotometry; D016896:Treatment Outcome; D014810:Vitamin E / Q000008:administration & dosage / Q000627:therapeutic use*
D000975:Antioxidants; D011837:Radiation-Protective Agents; D015842:Serine Proteinase Inhibitors; D014810:Vitamin E; D008315:Malondialdehyde; D007611:Aprotinin; D010431:Pentoxifylline